About Us

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

ResMed.com | Facebook | Twitter | LinkedIn

Our story

In 1981 Professor Colin Sullivan and colleagues at the University of Sydney described and developed nasal continuous positive airway pressure (CPAP), the first successful non-invasive treatment for obstructive sleep apnea (OSA).

After publishing the successful results in Lancet, Sullivan, who had patented the technology, sought a compatible partner to help commercialize this life-changing technology. In 1986 he approached Chris Lynch, managing director of the Baxter Centre for Medical Research and vice president of R&D for Baxter Healthcare, who in turn reached out to his Baxter coworker Dr. Peter Farrell.

In 1987 Farrell, on behalf of Baxter, invested in Sullivan’s technology to further evolve the CPAP prototype and undertake clinical trials on a group of patients with severe sleep apnea. In 1989, after Baxter decided not to enter the sleep apnea market for a variety of reasons, Farrell founded ResMed (short for “Respiratory Medicine”) to buy Sullivan’s sleep technology from Baxter and to commercialize his prototype CPAP device to allow scalable device production – in other words, to bring CPAP to the world at large.

Since then, ResMed has delivered on Farrell’s promise: making CPAP masks, CPAP machines and in-home life support ventilators more comfortable, quieter and easier to use. It has also become the world leader in remote and self-monitoring software, with more than three million patients worldwide remotely monitored by clinicians. The software is shown to increase patients’ therapy adherence rates and clinicians’ business efficiencies.

Recent notable products include:

  • 2017:AirTouch F20, a memory foam cushion full face mask for revolutionary comfort
  • 2017:AirMini, the world’s smallest CPAP machine, weighing less than one pound, featuring waterless humidification and operated with a smartphone app
  • 2016:AirFit 20nasal and full face masks with InfinitySeal silicone cushions, found to fit 99 and 97 percent of wearers1-4, respectively
  • 2015: S+, the world’s first non-contact sleep tracker (the next-generation tracker is theSleepScore Max, released in November 2017 by SleepScore Labs, a joint venture of ResMed, Dr. Oz and Pegasus Capital)
  • 2014:Air10 SeriesCPAP machines that are smaller, quieter and all cloud-connected
  • 2014:AirSense 10 AutoSet for Her, the world’s only CPAP designed to treat female-specific, mild-to-moderate obstructive sleep apnea
  • 2014:Astral, a lightweight, portable life support ventilator for in-home use. In 2016, it became theworld's first ventilator with cloud-connected remote monitoring

Revenues for ResMed's first fiscal year in 1990 were less than $1 million, and there were only 9 employees. As of July 2017, ResMed is an S&P 500 company with a market cap exceeding $10 billion and yearly revenues above $2 billion. It employs more than 6,000 people globally and operates in more than 120 countries.

Today, ResMed founder Peter Farrell is Chairman of ResMed’s Board of Directors. His son Michael "Mick" Farrell, a ResMed employee for more than 15 years, has been CEO since 2013.

1 ResMed AirFit F20 internal Australian fitting study of existing CPAP patients conducted between March–April 2016.

2 ResMed AirFit F20 internal USA fitting study of existing CPAP patients conducted April 2016.

3 ResMed AirFit F20 internal EU and APAC fitting study of existing CPAP patients conducted June 2016.

4 ResMed AirFit N20 internal international fitting study of new and existing CPAP patients, conducted Nov 2015.

Our mission

Our mission is to change 20 million lives by 2020. We're proud to make equipment and connected health solutions that give those with sleep apnea, COPD and other respiratory diseases the gift of breath.

Aims and objectives

Our aim is to deliver life-changing products and connected health solutions to patients worldwide with sleep apnea or other respiratory conditions, and to spread awareness about these conditions and treatments. Our objective is two-fold:

  • Provide life-changing diagnoses and treatments to patients with sleep apnea, COPD and other respiratory diseases; and
  • Enable remote and self-monitoring via our therapy devices to improve patients’ experiences, outcomes and health, as well as clinicians’ patient management efficiency.

We sell a comprehensive range of products in more than 120 countries worldwide through direct offices and a network of distributors. Plus more than 5 million ResMed devices are cloud-connected, sharing actionable data with clinicians and patients themselves to improve their therapy experience, adherence and overall health.

Dedicating 7 percent of annual revenue to research and development, we are committed to advancing innovative technology in sleep and respiratory medicine, to commercializing innovative products that incorporate these technologies around the world, and exercising the highest standards of ethics and quality at all times.


Email Alerts

Email Adress Email Address: *
Mailing Lists *

Enter the code shown above.